WASHINGTON — The Food and Drug Administration has approved Winrevair, or sotatercept-csrk, for adults with pulmonary arterial hypertension, adding a new biological pathway to a treatment field that has largely focused on relaxing pulmonary blood vessels. Merck announced the March 26 approval, describing Winrevair as the first activin-signaling inhibitor cleared for the disease. In the pivotal STELLAR study, patients receiving sotatercept on top of existing therapy improved their six-minute walk distance by a placebo-adjusted 41 meters at week 24 and experienced an 84% reduction in the risk of death or a first clinical-worsening event. The FDA's Drug Trials Snapshot summarizes the evidence supporting the decision.

Pulmonary arterial hypertension, or PAH, is a progressive disorder in which small arteries in the lungs become narrowed and remodeled, increasing resistance to blood flow and forcing the right side of the heart to pump against abnormally high pressure. Over time, that strain can lead to right-heart failure and death. Existing drugs target nitric oxide, endothelin and prostacyclin pathways to dilate vessels and improve symptoms. Sotatercept approaches the disease differently by binding selected activin-family ligands involved in abnormal cellular proliferation and vascular remodeling.

A pivotal trial added therapy rather than replacing it

The 323-patient STELLAR trial enrolled adults with symptomatic PAH who were already receiving stable background treatment. Participants were randomized to sotatercept or placebo every three weeks. The peer-reviewed New England Journal of Medicine report, published in 2023, showed the primary endpoint improvement in six-minute walk distance and favorable results across multiple secondary measures, including pulmonary vascular resistance, functional class and time to death or clinical worsening.

That design is important because Winrevair enters a treatment environment in which many patients already take two or three PAH drugs. The approval is not based on replacing those therapies; it is based on adding a new mechanism to them. An American College of Cardiology analysis of the STELLAR results noted the potential importance of targeting vascular remodeling in addition to vasodilation.

The mechanism targets an imbalance in growth signaling

Sotatercept is a fusion protein that acts as a ligand trap for members of the transforming growth factor-beta superfamily. In PAH, signaling through activin pathways is thought to favor excessive proliferation of cells in pulmonary blood vessels. By binding those ligands, sotatercept is intended to rebalance growth-promoting and growth-inhibiting signals and reduce pathological remodeling.

That mechanism distinguishes the drug from endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators and prostacyclin-pathway agents. Cleveland Clinic's contemporaneous clinical review described STELLAR as evidence that disease-modifying strategies may complement the established hemodynamic approach to PAH.

Benefits come with monitoring requirements

The approval also brings safety considerations that will require routine laboratory monitoring. Sotatercept can increase hemoglobin and cause thrombocytopenia, creating risks related to excessive red-cell mass and bleeding. Other adverse effects reported in trials include nosebleeds, telangiectasia, headache, dizziness, diarrhea and increased blood pressure. Clinicians are instructed to check hemoglobin and platelet counts before the first five doses and subsequently as clinically indicated.

Because PAH patients can be medically fragile and often receive anticoagulants or multiple vasodilators, those safety issues will influence how the drug is integrated into practice. The treatment is administered by subcutaneous injection every three weeks, creating a different logistical profile from continuously infused prostacyclin therapies but still requiring specialized follow-up.

A major change in a high-risk disease

The magnitude of the clinical-worsening result is likely to attract attention because PAH remains serious despite substantial therapeutic progress. The STELLAR endpoint included death, lung transplantation, PAH-related hospitalization and other markers of deterioration. A reduction in those events on top of background therapy suggests that the drug's impact may extend beyond exercise capacity.

Reuters reported that the approval gives Merck a potential new growth product following its acquisition of Acceleron Pharma, which developed sotatercept. The commercial context matters, but the clinical question is more consequential: whether the benefits seen in STELLAR persist over longer follow-up and across a broader mix of patients than those enrolled in the trial.

The FDA decision does not eliminate the need for established PAH therapies, nor does it establish that every patient should receive sotatercept. It does, however, expand the therapeutic model. For the first time, U.S. clinicians have an approved PAH drug aimed directly at activin signaling and vascular remodeling rather than primarily at vasodilation.

As of Saturday, Winrevair's approval rests on a randomized trial showing a 41-meter placebo-adjusted gain in walking distance and a large reduction in death or clinical-worsening risk. The next phase will occur in specialty clinics, where physicians will determine how to sequence the therapy, which patients benefit most and whether its trial performance translates into sustained improvements in routine care.